NEW YORK, May 21 – Agilent Technologies said Monday it had reached an agreement with Harvard University to jointly develop nanopore technology for the analysis of nucleic acids.
The terms of the multiyear deal were not disclosed, but Agilent did say the project could be extended.
The company said it would work with Harvard to develop technology that converts nucleotide sequences into electronic signatures, helping to speed up the sequencing process. Agilent did not say when it expected to release nanopore technology to market.
“The speed and simplicity of this new technology is expected to greatly expand access to genetic information for use in drug discovery and development, and in the prediction, diagnosis and treatment of disease,” Agilent said in a statement. “Nanopore technology may also accelerate advances in personalized medicine so that therapies may be tailored to an individual's particular disease.”
Agilent also said that it hopes to eventually apply the technology to proteins.
A company representative was not immediately available for comment.